PF-06823859 low + Placebo Arm + PF-06823859 high
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dermatomyositis
Conditions
Dermatomyositis
Trial Timeline
Jan 23, 2018 → Nov 28, 2022
NCT ID
NCT03181893About PF-06823859 low + Placebo Arm + PF-06823859 high
PF-06823859 low + Placebo Arm + PF-06823859 high is a phase 2 stage product being developed by Pfizer for Dermatomyositis. The current trial status is completed. This product is registered under clinical trial identifier NCT03181893. Target conditions include Dermatomyositis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03181893 | Phase 2 | Completed |
Competing Products
14 competing products in Dermatomyositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| M5049 high dose + Placebo | Merck | Phase 2 | 52 |
| BAF312 + Placebo | Novartis | Phase 2 | 52 |
| MEDI7734 + Placebo | Amgen | Phase 1 | 32 |
| Etanercept + Placebo | Amgen | Phase 1 | 32 |
| Dazukibart | Pfizer | Phase 3 | 76 |
| Anti-Beta Interferon (PF-06823859) | Pfizer | Phase 2 | 51 |
| Tofacitinib | Pfizer | Phase 1 | 32 |
| Emapalumab | Swedish Orphan Biovitrum | Phase 2 | 51 |
| human immunoglobulin G + Placebo | CSL | Phase 3 | 76 |
| Empasiprubart IV | Argenx | Phase 2 | 49 |
| GLPG3667 + Placebo | Galapagos | Phase 2 | 47 |
| Lenabasum 20 mg + Lenabasum 5 mg + Placebo | Corbus Pharmaceuticals | Phase 3 | 69 |
| JBT-101 + Placebo | Corbus Pharmaceuticals | Phase 2 | 44 |